SNPMiner Trials (Home Page)
Report for Clinical Trial NCT00255658
 Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene 
      This phase I trial is studying the side effects and best dose of temsirolimus when given
      together with sorafenib in treating patients with unresectable or metastatic solid tumors.
      Sorafenib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood
      flow to the tumor. Giving sorafenib together with temsirolimus may kill more tumor cells.
    
NCT00255658  Unspecified Adult Solid Tumor, Protocol Specific 
  3  Interventions 
 Name: sorafenib tosylate
Description: Given orally
 Type: Drug
Group Labels:  1  Treatment (sorafenib tosylate, temsirolimus)  
 Name: temsirolimus
Description: Given IV
 Type: Drug
Group Labels:  1  Treatment (sorafenib tosylate, temsirolimus)  
 Name: laboratory biomarker analysis
Description: Correlative studies
 Type: Other
Group Labels:  1  Treatment (sorafenib tosylate, temsirolimus)  
  
Primary Outcomes 
 Measure: Maximum tolerable dose (MTD) and recommended dose for phase II determined by dose-limiting toxicities (DLT) graded according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 Time: 4 weeks
  
Purpose: Treatment
Allocation: N/A
Single Group Assignment 
There is one SNP
SNPs
To analyze the biologic effects of BAY 43-9006 and CCI-779 on downstream targets of the
      P13K/Akt/mTOR and Raf signaling pathways. --- P13K ---